Article

Differences in historical operational biomarker positivity between two plasma-based comprehensive genomic profiling platforms in Japan: a nationwide C-CAT study

2026-08-12

Abstract excerpt

<title>Abstract</title> <p>Background A nationwide study found a large historical difference in operational biomarker positivity between liquid comprehensive genomic profiling platforms. Whether case mix, calendar time, or facility composition explained it was uncertain. Methods We analyzed 14,878 FoundationOne Liquid CDx (F1L) and 2,042 Guardant360 CDx (G360) records through March 31, 2025. The patient-level c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 32a796ec-f19b-5ae3-92b3-ad36ca03c114
DOI: 10.21203/rs.3.rs-10573553/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differences in historical operational biomarker positivity between two plasma-based comprehensive genomic profiling platforms in Japan: a nationwide C-CAT studyDOI 10.21203/rs.3.rs-10573553/v1Read

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read

Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health-Foundation Medicine Clinico-Genomic Databases, Flatiron Health Research Databases, and the National Cancer Institute SEER Population-Based Cancer RegistrySemantic proximity Read

A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study).Semantic proximity Read

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.Semantic proximity Read

Organ-specific cancer biomarker identification: a ten-year single-center study in southern ChinaSemantic proximity Read

Bridging Discovery and Treatment: Cancer BiomarkerSemantic proximity Read

Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers.Semantic proximity Read

Real-World Landscape of Genomic Medicine in Breast Cancer Revealed by the C-CAT Database: Reappraisal of Drug Accessibility and Clinical Utility in 6,307 PatientsSemantic proximity Read

Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity Read

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid TumorsSemantic proximity Read

[Current Status and Regulatory Issues of Companion Diagnostics in Japan].Semantic proximity Read